US equities |
NVDA $186.64 ▲+2.78% MU $690.00 ▲+5.12% AMD $449.04 ▲+11.04% SPCX $134.27 ▲+8.62% AAPL $342.37 ▼-0.52% SNDK $835.06 ▲+3.55% MSFT $530.61 ▼-0.99% TSLA $358.22 ▲+4.23%
FinancialContent

Attovia Therapeutics, Inc. - Common Stock (NQ:ATTO)

15.27 +0.27 (+1.80%)
Delayed Quote Updated: 4:00 PM EST, Nov 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Attovia Therapeutics, Inc. - Common Stock

News headline image
Attovia Therapeutics Reports Sustained Itch Relief in Small Study, Plans Phase 2 Trials ↗
Attovia Therapeutics (NASDAQ:ATTO) reported 12-week results from a small phase 1b study of its experimental itch treatment ATTO-1310, saying a single dose produced sustained responses in patients with... 
Via MarketBeat
News headline image
Attovia Therapeutics Announces Positive Topline 12-Week Results from Phase 1b Study of ATTO-1310 in Patients with Chronic Pruritus and High-Itch Atopic Dermatitis
From Attovia Therapeutics, Inc.
Via GlobeNewswire
News headline image
Attovia Therapeutics to Participate in Upcoming Investor Conferences
From Attovia Therapeutics, Inc.
Via GlobeNewswire
News headline image
Attovia Therapeutics to Present New Data on ATTO-1310 and ATTO-2306 at EADV 2026 and Fall Clinical Dermatology Conference 2026
From Attovia Therapeutics, Inc.
Via GlobeNewswire
News headline image
Attovia Therapeutics to Participate in Upcoming Investor Conferences
From Attovia Therapeutics, Inc.
Via GlobeNewswire
News headline image
Attovia Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update
From Attovia Therapeutics, Inc.
Via GlobeNewswire
News headline image
Attovia Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
From Attovia Therapeutics, Inc.
Via GlobeNewswire